High Cure Rates and Reduced Long-Term Toxicity in Pediatric Hodgkin's Disease: The German-Austrian Multicenter Trial DAL-HD-90
Authors:
- Günther SchellongGSGünther Schellong
- Richard PötterRPRichard Pötter
- Jürgen BrämswigJBJürgen Brämswig
- Wolfgang WagnerWWWolfgang Wagner
- Franz-Josef ProttFPFranz-Josef Prott
- Wolfgang DörffelWDWolfgang Dörffel
- Dieter KörholzDKDieter Körholz
- Georg MannGMGeorg Mann
- Bettina RathBRBettina Rath
- Alfred ReiterARAlfred Reiter
- Gerhard WeissbachGWGerhard Weissbach
- Marianne RiepenhausenMRMarianne Riepenhausen
- 1 December 1999
- journal article
- pediatric oncology
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 17 (12) , 3736-3744
Abstract
PURPOSE: To further reduce therapy-related late effects in patients with pediatric Hodgkin's disease (HD) while maintaining the high cure rates achieved with vincristine, prednisone, procarbazine, and doxorubicin (OPPA) or OPPA/cyclophosphamide, vincristine, prednisone, and procarbazine (COPP) chemotherapy and involved-field radiotherapy. The risk of testicular dysfunction was addressed by substituting etoposide for procarbazine (OEPA) in the induction therapy for boys. Radiation doses and fields were further reduced. PATIENTS AND METHODS: Three hundred nineteen boys and 259 girls younger than 18 years with previously untreated HD, enrolled onto the study between 1990 and 1995, were allocated to treatment group (TG)1 (early stages), TG2 (intermediate stages), or TG3 (advanced stages). All groups underwent two cycles of OEPA (boys) or OPPA (girls) for induction chemotherapy. TG2 and TG3 continued on additional two or four cycles, respectively, of COPP. Low-dose radiotherapy was given to the initially involved sites, ie, reduced involved fields. RESULTS: Initial response to OPPA or OEPA induction was virtually identical. Eight of 578 patients experienced early progression of HD. Thirty-seven relapses, three secondary tumors, and no secondary leukemias have been recorded, with a median follow-up duration of 5.1 years (maximum, 8.1 years). Thirteen of 578 patients died. The probability of 5-year event-free survival/overall survival is 91%/98% in the total group, 94%/97% with OPPA, and 89%/98% with OEPA induction therapy. Risk factor analysis showed two significant prognostic factors: histologic subtype NS2 and “B” symptoms. OEPA induction therapy, large mediastinal tumor, and age were not significant. Preliminary studies of testicular function indicate a lower risk of germ cell damage than previously documented with OPPA. CONCLUSION: OEPA is a satisfactory alternative to OPPA. Radiotherapy can be confined to involved sites when combined with appropriate chemotherapy. The DAL-HD-90 regimen represents a comprehensive treatment program for all stages of pediatric HD and offers a favorable benefit/risk ratio, combining excellent disease control, moderate acute toxicity, and reduced long-term toxicity.Keywords
This publication has 42 references indexed in Scilit:
- 11 Treatment of children and adolescents with Hodgkin's disease: the experience of the German-Austrian Paediatric study groupBailliere's Clinical Haematology, 1996
- Present and future strategies of treatment in childhood Hodgkin's lymphomasAnnals of Oncology, 1996
- ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: the Stanford experience.Journal of Clinical Oncology, 1994
- Treatment of pediatric hodgkin disease tailored to stage, mediastinal mass, and age an italian (aieop) multicenter study on 215 patientsCancer, 1993
- Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin's disease.Journal of Clinical Oncology, 1993
- Treatment of children with Hodgkin's disease – Results of the German Pediatric Oncology GroupAnnals of Oncology, 1992
- Hodgkin's disease in children: Treatment with MOPP and low‐dose, extended field irradiation without laparotomy late results and toxicityMedical and Pediatric Oncology, 1990
- The Challenge of Pediatric Hodgkin's Disease–Where is the Balance Between Cure and Long-Term Toxicity?: A report of the West German multicenter studies DAL-HD-78, DAL-HD-82 and DAL-HD-85Leukemia & Lymphoma, 1990
- Pediatric hodgkin's disease: pulmonary, cardiac, and thyroid function following combined modality therapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1989
- Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin's disease.Journal of Clinical Oncology, 1987